Overview

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Two cohorts of patients will be enrolled: Cohort A will consist of patients who are current smokers, and Cohort B will consist of patients who are current nonsmokers. There will be 24 patients enrolled in each cohort. Nonsmokers are patients who have not consumed tobacco or nicotine-containing products for 1 year before the start of the study. Patients classified as current smokers must have smoked a minimum of 10 cigarettes per day for up to 1 year. Patients who have smoked 1-9 cigarettes per day for up to 1 year, or more than 10 cigarettes per day for less than 1 year will not be eligible for this study.
Phase:
Phase 1
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborator:
Bayer
Treatments:
Erlotinib Hydrochloride
Niacinamide
Sorafenib